#$BYSI
BeyondSpring ($BYSI) – 13G holder update

• Holder: Decheng Capital Management III (Cayman)
• Stake: now 7.5% (about $2M)
• Filed: Oct 29 · Schedule 13G/A

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#Investing #Stocks #13G #ElixStocks
Decheng Capital Management III (Cayman), LLC: 7.5% of BeyondSpring ($BYSI)
Schedule 13G/A filed Oct 29. Who filed, the stake, and how it changed.
elixstocks.com
October 29, 2026 at 8:16 PM
🚨 $BYSI
(a) BeyondSpring Inc. held its 2026 annual meeting of shareholders on October 13, 2026. A total of 20,905,921 of the Company’s ordinary shares were present or represented by proxy at the meeting, representing approximately 50.84% of the Company’s 41,119,820 ordinary shares that were outst...
SEC Filing: BYSI
Click to view the official SEC document.
www.sec.gov
October 13, 2026 at 8:36 PM
🚨 $BYSI
On September 30, 2026, BeyondSpring Inc. completed the closing of the previously disclosed transactions under the Share Purchase and Collaboration Agreement, dated as of September 28, 2026 , by and among the Company, Dalian Wanchunbulin Pharmaceuticals Ltd., a limited liability company in...
SEC Filing: BYSI
Click to view the official SEC document.
www.sec.gov
October 7, 2026 at 11:40 AM
🚨 $BYSI
On September 30, 2026, BeyondSpring Inc. completed the closing of the previously disclosed transactions under the Share Purchase and Collaboration Agreement, dated as of September 28, 2026 , by and among the Company, Dalian Wanchunbulin Pharmaceuticals Ltd., a limited liability company in...
SEC Filing: BYSI
Click to view the official SEC document.
www.sec.gov
October 6, 2026 at 8:41 PM
🚨 $BYSI
On September 29, 2026, BeyondSpring Inc. received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because the Company’s market value of listed securities has fallen below $35 million for the last 30 consecutive b...
SEC Filing: BYSI
Click to view the official SEC document.
www.sec.gov
October 2, 2026 at 10:06 PM
📊 Stock movers right now:

BKYI: $3.13 (+86.3%)
DCX: $3.51 (-43.1%)
BYSI: $0.67 (-40.2%)
AIXC: $1.04 (-37.3%)
IOVA: $14.95 (+36.0%)

More: https://suggestionbox.live/planet-markets
September 29, 2026 at 7:00 PM
🚨 $BYSI
On September 29, 2026, the Company issued a press release announcing, among other things, the transactions described above, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
SEC Filing: BYSI
Click to view the official SEC document.
www.sec.gov
September 29, 2026 at 11:04 AM
📊 Stock movers right now:

BYSI: $1.12 (+44.1%)
ARAY: $0.30 (+39.4%)
ACET: $6.35 (-29.6%)
ABLV: $1.67 (+28.1%)
BTAI: $0.04 (-27.5%)

More: https://suggestionbox.live/planet-markets
September 29, 2026 at 7:00 AM
$BYSI — BeyondSpring's plinabulin Fast Track Designation and recent price surge dominated recent analyses.

FDA Fast Track Designation for plinabulin in post-ICI non-squamous NSCLC. Longer-term downtrend prior to recent rally (-37.4% 91-day).

https://market-scanner.net/tickers/BYSI.US

#ai #trading
BYSI.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
September 29, 2026 at 12:36 PM
📉 BYSI (BeyondSpring) -10.5% since we peeled back the filing
Filed: Sep 18, 2026 | 16:30 ET | Now: Sep 21, 2026 | 06:32 ET

At filing: $0.7498 to Now: $0.6710
Score: 9/10 | Negative

Headlines are late. Filings aren't.

Read the original breakdown (sourced from Wiseek):
September 21, 2026 at 10:34 AM
🚨 JUST IN: $BYSI
BeyondSpring receives Nasdaq bid-price delisting notice; 180-day cure window to March 16, 2027

#SEC #stocks #investing #BYSI #Regulatory
🔗 secwatch.observer
September 18, 2026 at 10:27 PM
🚨 $BYSI
On September 17, 2026, BeyondSpring Inc. received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC that, because the closing bid price for the Company’s ordinary shares, par value $0.0001 per share , has fallen below $1.00 per share for 30 c...
SEC Filing: BYSI
Click to view the official SEC document.
www.sec.gov
September 18, 2026 at 8:42 PM
$TNON jumped after repaying $5.16M in debt early, improving its balance sheet and reducing dilution risk. $AEON $NRSN $SLXN $CDT $INDP $BYSI $CRDF $LEXX $CYCN

www.biopharmcatalyst.com/news/2026/bi...
Daily Updates 09/10/26
export-download.canva.com
September 10, 2026 at 8:30 PM
Yesterday was our last day with Tolu - our student summer intern through University of Alberta’s Black Youth for Social Innovation (BYSI) program.

Tolu was a wonderful addition to our team & we wish her all the best as she finishes her last year of her political science degree. #abpoli
September 1, 2026 at 3:25 PM
📊 Stock movers right now:

CTXR: $0.56 (-25.6%)
BTAI: $0.89 (-25.2%)
CUE: $27.64 (-19.2%)
BYSI: $0.71 (-15.2%)
SWMR: $47.08 (+13.2%)

More: https://suggestionbox.live/planet-markets
August 18, 2026 at 7:00 AM
🚨 $BYSI
On August 14, 2026, BeyondSpring Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
SEC Filing: BYSI
Click to view the official SEC document.
www.sec.gov
August 14, 2026 at 9:25 PM
#BYSI BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

https://www.stocktitan.net/news/BYSI/beyond-spring-reports-second-quarter-2026-financial-results-and-bff60ytc752d.html
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring (NASDAQ: BYSI) reported second-quarter 2026 results and highlighted new clinical and leadership developments around its lead asset, Plinabulin. Updated ASCO 2026 Phase 2 data in metastatic NSCLC post-ICI showed median progression-free survival of 7.0 months, median duration of response of 9.3 months, disease control rate of 79.5%, and a 24‑month overall survival rate of 58.0%, with median overall survival not yet reached.AACR 2026 preclinical data indicated that Plinabulin improved complete tumor regression, survival and tolerability when combined with certain TOP1-based ADCs. The company is preparing the 442‑patient confirmatory DUBLIN‑4 Phase 3 study. Q2 2026 R&D and G&A expenses were $1.0 million and $0.8 million, respectively, net loss from continuing operations was $1.8 million, and cash, cash equivalents and short-term investments totaled $6.5 million at June 30, 2026. A leadership transition effective July 1, 2026 installed Min Qiu as CEO and Na Li as CFO.
www.stocktitan.net
August 14, 2026 at 9:15 PM
Trading Resumed for $BYSI BeyondSpring Inc. Ord Shrs | at 12:26:49 ET on NASDAQ | 2026-08-13
August 14, 2026 at 2:56 AM
Trading Halted for $BYSI BeyondSpring Inc. Ord Shrs | at 12:21:49.456 ET on NASDAQ | Volatility Trading Pause | 2026-08-13
August 14, 2026 at 2:56 AM
Trading Resumed for $BYSI BeyondSpring Inc. Ord Shrs | at 12:26:49 ET on NASDAQ | 2026-08-13
August 14, 2026 at 2:52 AM
Trading Halted for $BYSI BeyondSpring Inc. Ord Shrs | at 12:21:49.456 ET on NASDAQ | Volatility Trading Pause | 2026-08-13
August 14, 2026 at 2:52 AM
$LEXX teams with PegBio to test DehydraTECH with GLP-1; may lead to licensing if trials boost efficacy for diabetes, obesity, or MASH. $BYSI $INO $ABEO $OMER $OTLK $JUNS $OPRX $BTTC $HUMA

www.biopharmcatalyst.com/news/2026/be...
Daily Updates 08/13/26
export-download.canva.com
August 13, 2026 at 8:30 PM
"...nein dem ZDF gebe ich kein Interview. Nur alternativen Medien. Das System ist schuld. Das System ist schuld..."

Ja klar, Bysi Baybie und Tschüss ...
May 16, 2024 at 6:41 PM